Capricor Therapeutics, Inc.
CAPR
$6.39
-$0.21-3.18%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 16.56% | 29.96% | |||
| Gross Profit | -16.56% | -452.38% | |||
| SG&A Expenses | -6.52% | 41.98% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 10.95% | 32.69% | |||
| Operating Income | -10.95% | -224.55% | |||
| Income Before Tax | -6.23% | -242.74% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -6.23% | -242.74% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -6.23% | -242.74% | |||
| EBIT | -10.95% | -224.55% | |||
| EBITDA | -10.80% | -235.66% | |||
| EPS Basic | -6.06% | -234.27% | |||
| Normalized Basic EPS | -6.72% | -237.74% | |||
| EPS Diluted | -6.06% | -234.27% | |||
| Normalized Diluted EPS | -6.72% | -237.74% | |||
| Average Basic Shares Outstanding | 0.16% | 2.53% | |||
| Average Diluted Shares Outstanding | 0.16% | 2.53% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||